Rebrain services provide precise brain targeting for DBS neurosurgery, enhancing patient outcomes in Parkinson’s disease and Essential Tremor treatments

RebrAIn’s news

RebrAIn publishes OPTIVIM trial results in Neurosurgery: a major breakthrough in deep brain stimulation

An innovative and automated method

RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target, without the need for:

  • complex anatomical atlases,
  • advanced imaging acquisitions (such as DTI),
  • or intraoperative electrophysiological recordings.

This approach enables rapid, reproducible, and personalized targeting, paving the way for a more accessible practice of functional neurosurgery.

“This clinical validation demonstrates that AI can truly assist neurosurgeons and make advanced treatments accessible to more patients” said Prof. Emmanuel Cuny.

Results of the OPTIVIM study

The OPTIVIM trial included 22 patients who underwent direct bilateral electrode implantation at two specialized centers.

  • Standardized Fahn-Tolosa-Marin scores improved by an average of 61.3% (95% CI: 53.7–68.9).
  • Accelerometry demonstrated up to 84% reduction in postural tremor amplitude.
  • Quality of life (mPDQ-39) improved by 55%.
  • Active contacts were mainly located in the PSA (59%) and the VIM (20%), confirming the anatomical relevance of the targeting.

These results, obtained under general anesthesia, are comparable to those reported in the literature for DBS under local anesthesia and ablative techniques.

“This milestone confirms our vision: making precision neurosurgery scalable and accessible worldwide” said David Caumartin, CEO of RebrAIn.

Towards a new era in functional neurosurgery

The publication of the OPTIVIM results in Neurosurgery marks a key milestone for RebrAIn. It confirms the scientific and clinical robustness of RebrAIn’s algorithm and grants it international recognition within the neurosurgical community.

RebrAIn’s approach could redefine the standards of deep brain stimulation. By simplifying the procedure and increasing its reproducibility, RebrAIn’s service paves the way for broader adoption of this therapy and significant improvements in the management of patients with severe tremor.

Our latest public updates

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...